issues with semaglutide Benefits of GLP-1 Semaglutide: Double-edged Sword with Risks

BCS Class I drugs are not likely to be impacted by common excipients

Using precise radiofrequency energy, the procedure targets and eliminates unwanted lesions with minimal discomfort and downtime

Primary Uses and FDA Approvals Ozempic Primary FDA approval: Type 2 diabetes management Secondary benefit: Weight loss Typical weekly doses: 0.25 mg to 2 mg Wegovy Primary FDA approval: Chronic weight management Specifically approved for: Adults with BMI 30, or Adults with BMI 27 with at least one weight-related condition Typical weekly doses: 0.25 mg to 2.4 mg Key Differences (Wegovy vs Ozempic) Dosing Protocol Wegovy follows a more gradual dose escalation pattern and reaches a higher maximum dose than Ozempic

Unlike its predecessors, the REWIND trial was not aimed at uncovering cardiovascular safety of GLP-1RAs